![Crystalline (2S)-3-[(3S,4S)-3-[(1R)-1-hydroxyethyl]-4-(4-methoxy-3-{[1-(5-methylpyridin-2-yl)azetidin-3-yl]oxy}phenyl)-3-methylpyrrolidin-1-yl]-3-oxopropane-1,2-diol](/docs/US/2018-09-04/US10065942B2/abs.jpg.600x600.jpg)
- Patent Title: Crystalline (2S)-3-[(3S,4S)-3-[(1R)-1-hydroxyethyl]-4-(4-methoxy-3-{[1-(5-methylpyridin-2-yl)azetidin-3-yl]oxy}phenyl)-3-methylpyrrolidin-1-yl]-3-oxopropane-1,2-diol
-
Application No.: US15505740Application Date: 2015-08-28
-
Publication No.: US10065942B2Publication Date: 2018-09-04
- Inventor: Ping Huang , Seth Dietrich Ribe
- Applicant: Eli Lilly and Company
- Applicant Address: US IN Indianapolis
- Assignee: Eli Lilly and Company
- Current Assignee: Eli Lilly and Company
- Current Assignee Address: US IN Indianapolis
- Agent Danny L. Wood
- Priority: WOPCT/CN2014/085925 20140904
- International Application: PCT/US2015/047415 WO 20150828
- International Announcement: WO2016/036596 WO 20160310
- Main IPC: C07D401/14
- IPC: C07D401/14 ; A61K31/4439 ; A61K31/4985
![Crystalline (2S)-3-[(3S,4S)-3-[(1R)-1-hydroxyethyl]-4-(4-methoxy-3-{[1-(5-methylpyridin-2-yl)azetidin-3-yl]oxy}phenyl)-3-methylpyrrolidin-1-yl]-3-oxopropane-1,2-diol](/abs-image/US/2018/09/04/US10065942B2/abs.jpg.150x150.jpg)
Abstract:
The invention provides crystalline (2S)-3-[(3S,4S)-3-[(1R)-1-hydroxyethyl]-4-(4-methoxy-3-{[1-(5-methylpyridin-2-yl)azetidin-3-yl]oxy}phenyl)-3-methylpyrrolidin-1-yl]-3-oxopropane-1,2-diol, and pharmaceutical compositions thereof. The invention further provides methods of using this compound to treat overactive bladder.
Public/Granted literature
Information query
